熱門資訊> 正文

Neoleukin Therapeutics GAAP每股收益为-1.00美元，击败0.03美元

2024-05-10 19:46

Neoleukin Therapeutics press release (NASDAQ:NGNE): Q1 GAAP EPS of -$1.00 beats by $0.03.
Cash, cash equivalents and investments as of March 31, 2024 were $169.5 million. The Company expects current cash, cash equivalents and marketable securities to fund operations into the second half of 2026.

More on Neoleukin Therapeutics

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers
Historical earnings data for Neoleukin Therapeutics
Financial information for Neoleukin Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。